AIP
HAE icon

Almanack Investment Partners’s Haemonetics HAE Stock Holding History

Almanack Investment Partners’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-60
Closed -$4K – 592
2022
Q3 		$4K Buy
+60
New +$4.31K ﹤0.01% 621

Other funds holding HAE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Almanack Investment Partners's HAE Position: Q4 2022 in Review

Almanack Investment Partners sold out of Haemonetics (HAE) in Q4 2022, closing a stake of 60 shares — an estimated $4K sold.

Almanack Investment Partners first reported a position in HAE in Q3 2022 and held it in 1 quarter. The position peaked at $4K in Q3 2022. 294 funds tracked by Wall St. Rank hold HAE as of Q4 2022.

  • Almanack Investment Partners reported no remaining Haemonetics position as of Q4 2022 after selling out during the quarter.
  • Almanack Investment Partners sold 60 Haemonetics shares in Q4 2022, an estimated $4K.
  • Almanack Investment Partners first reported a position in Haemonetics in Q3 2022 and held it in 1 quarter.
  • Almanack Investment Partners's Haemonetics position peaked at $4K in Q3 2022.
  • 294 funds tracked by Wall St. Rank held Haemonetics as of Q4 2022.

Based on Almanack Investment Partners's 13F filing for Q4 2022, filed 9 Feb 2023.